IU researchers won't rest until the testicular cancer survival rate is 100 percent.
portrait of dr. larry einhorn

Testicular Cancer Research

Four decades ago, a man diagnosed with testicular cancer had a survival rate of just 5 percent. Today, that number is 95 percent.

The tables turned on testicular cancer thanks to a chemotherapy regimen developed by IU School of Medicine’s Larry Einhorn, MD. Today, hundreds of thousands of men around the world are alive because of this treatment protocol.

For these survivors, IU research has led to the gift of a long life. But the IU team still isn’t satisfied. They continue to chip away at the survival rate, finding ways to save men who do not respond to initial therapies. For example, our researchers are collaborating with bioengineers on a compound to signal the immune system to attack testis cancer cells.

IU researchers are also focused on reducing the “cost of the cure” – the long-term side effects that sometimes come with treatment. We lead a global team of researchers looking to reduce the toll of treatment, including tinnitus, hearing loss, cardiovascular issues, and numbness in extremities. 

You can help us achieve these goals. IU remains the international leader in testis cancer research and care, drawing patients from Indiana and around the world. With your support, we will have more answers waiting for them.

Support our research

a portrait of lois travis

Truly Healed

Lois Travis, MD, brings together scientists from across disciplines worldwide to cancer survivorship. Her goals are to identify, reduce, and eliminate the lasting effects of cancer treatment.

portrait of john cleland and larry einhorn

Larry Einhorn: The Breakthrough, The Cure, The Vision, The Legacy, The Teacher

Lawrence Einhorn, MD, cured testis cancer. But that wasn’t good enough for him. He has continued refining the treatment to spare patients some of the most awful side effects in the decades since.

Video

Testicular Cancer Research

Nabil Adra, MD, MSc, assistant professor of clinical medicine, shares the goals and importance of testicular cancer research conducted at Indiana University.

Simon Says Series graphic

Simon Says Expert Series

To better connect IU’s nearly 300 cancer experts with our community, we’ve launched the “Simon Says Expert Series,” a monthly virtual event where you’ll have the opportunity to hear from cancer center experts about various topics and ask your questions. You’ll hear about the latest advances in cancer prevention, detection, treatment, and life after cancer. You can also suggest topics you’d like to learn about in the future. 

We hope you sign up, take part, and learn more from the experts at the IU Simon Comprehensive Cancer Center.  You can explore previous Simon Says topics by visiting our session archive.

Simon Says Expert Series